UCB´s anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP ...
(WorldNews Belgium)

Paediatric focal-onset seizures (FOS) account for around 60% of all epileptic seizures in children, which if uncontrolled can lead to life-long cognitive, emotional and physical consequences. UCB awaits decision from the European Commission (EC) on the potential approval of this new VIMPAT® license extension in the European Union. Brussels (Belgium), 24th July 2017 - 07:00 (CEST): UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a new license extension for its anti-epileptic drug (AED) VIMPAT (lacosamide) for use as monotherapy and adjunctive therapy in the treatment of focal-onset...